Category Archives: Pharma Marketing

Beth Thompson

Beth Thompson joins CMI as VP Qualitative Research for Pharma Industry Marketing Analysis

ATLANTA, Ga. /Advertising Industry Newswire/ — Beth Thompson has joined CMI as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research with a focus on the pharmaceuticals and life sciences industries. CMI Research is a leader in marketing research services and insight.

Beth ThompsonThompson commented: “I was thrilled when CMI extended the invitation to assume leadership of the qualitative team. The company has a strong reputation for providing solid approaches and impactful insights on a wide range of strategic business issues. I was especially intrigued with CMI’s approach to defining the paths customers take and then identifying the touch points and triggers that affect behavior. We uncover the real – often subconscious – critical elements that impact physicians’ and patients’ decisions whether to treat a condition and what medication to prescribe.”

“We are very pleased to have Beth leading our qualitative team,” Chet Zalesky, president and CEO of CMI. “She has earned a terrific reputation in the industry, both as a qualitative expert and a seasoned team leader.”

Thompson’s experience spans multiple industry verticals from financial services to healthcare insurance, with a particularly deep background in the pharmaceuticals and life sciences industries. She has conducted countless studies over the past two decades in pharmaceuticals, as well as in medical devices, surgical interventions and procedures, diagnostics, and biotechnology products.

Before joining CMI, Thompson managed her own qualitative consultancy for a number of years and has held senior positions leading qualitative research teams and conducting qualitative research for at Genactis, AlphaDetail, and GfK. She holds a PhD (ABD) in Political Science from Rutgers University and a BA in International Relations from the University of Michigan.

About CMI:

CMI is a full-service marketing research company that combines comprehensive market research expertise with marketing insight to provide clients with a deep understanding of their customers by identifying the choices they make and why. Since 1989, CMI has delivered unique solutions to uncover opportunities, optimize marketing strategies, and improve performance for clients in consumer and B2B markets. CMI’s experienced team of market research consultants leverages a wide range of qualitative and quantitative methods and technologies to translate research into insights and insights into actions. CMI serves primarily Fortune 1000 clients. For more information about CMI, visit http://www.cmiresearch.com/ .

CMI Research

Pfizer and CMI Research team at PMRG for: Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting

ATLANTA, Ga. /Advertising Industry Newswire/ — At the PMRG National Annual Conference March 10-12 in Maryland, Pfizer and CMI Research will present: “Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting.” The presentation will be based on actual results of a recent study conducted of mothers of children with a medical condition to evaluate opportunities for a medication. This research is a very powerful story of the patient journey from recognizing preliminary symptoms through diagnosis and treatment.

CMI ResearchPaul Gondek, Ph.D., vice president of client solutions, and Alisa Hamilton, vice president of research services for CMI, developed the presentation with Deanna Schwarz, Director of Business Analytics and Insights for Pfizer Established Products. As part of the “Thriving Professionally” track, they will share how research findings and insights can be presented in an engaging way to walk participants through a story and transform the way research findings are shared throughout an organization.

This year’s PMRG Annual National Conference (ANC) will focus on the intrinsic value that an evolved healthcare marketing researcher must bring to today’s global brands and organization – value as a forward-thinking consultant, who not only provides the insight, but the foresight to make those “now what?” recommendations and to thrive in any challenging environment. For more information about the conference: http://www.pmrg.org/ .

About CMI Research: CMI is a full-service marketing research company that combines comprehensive research expertise with marketing insight to provide clients with a deep understanding of their customers by identifying the choices they make and why. Since 1989, CMI has delivered unique solutions to uncover opportunities, optimize marketing strategies, and improve performance for clients in consumer and B2B markets.

CMI’s experienced team of market research consultants leverages a wide range of qualitative and quantitative methods and technologies to translate research into insights and insights into actions. CMI serves primarily Fortune 1000 clients. For more information about CMI, visit http://www.cmiresearch.com/ .

About Pfizer: Pfizer Inc. applies science and global resources to improve health and well-being at every stage of life. The company strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. With a diversified global health care portfolio that includes human and animal biologic and small molecule medicines and vaccines, and many of the world’s best-known consumer products; every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Consistent with a responsibility as the world’s leading biopharmaceutical company, Pfizer also collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on the company. To learn more about the Pfizer’s commitments, please visit http://www.pfizer.com/ .

Elixir of Life KI Therapy Serum

Product Launch: Elixir of Life KI Therapy Serum from E’shee Clinical Esthetic

PHILADELPHIA, Pa. /Advertising Industry Newswire/ — E’shee Clinical Esthetic announced a new skin care product based on a combination of stem cell and infrared nanotechnology. It is the most potent skin care formula that combines gene therapy (FGF-1 peptide) and Far Infrared Powder (FIR) to rejuvenate and restore the beauty of damaged or aging skin. This new Elixir of Life Serum helps to activate the body’s stem cells to repair damaged tissue and skin regeneration.

“Results are proven. The FGF-1 peptide – the stem cell activator – helps to increase new skin cell growth at least 10-20 times faster than with other skin care products,” says Nataly Giter, founder, E’shee Clinical Esthetic.

Elixir of Life is ideal for people with circulation problems due to external factors such as pollution, and physical problems due to illness, medications or smoking. It works to repair dark circles and broken capillaries; delays the overall skin aging process through skin repair and re-growth; and also works to properly heal and repair scar tissue.

People of all ages – men and women – will see physical results within 30 days. Skin will be healthier and firmer with a smoother and more even skin tone.

“Ultimately, this new product helps to restore blood flow; aids with toxin removal; repairs broken capillaries; and reverses skin damage. We are very excited to offer this to anyone wishing to dramatically improve their skin care,” says Giter.

About E’shee Clinical Esthetic:
E’shee was launched in 2009 by Nataly Giter, a hands-on skin care professional with more than 20 years of experience. Through research and practical experience, she learned about the most effective ingredients for advanced skin care and became associated with Dr. Chiu, a professor from Ohio University and the first global pioneer to clone the human FGF-1 gene.

Together with Dr. Chiu and their combined connections to industry professionals, they utilized FGF-1 to create an extraordinary anti-aging product line, using 99 percent pure FGF-1 peptide – the best quality available outside of the human body.

For more information on E’shee Clinical Esthetic, visit: www.esheeesthetic.com .

integrative logic atlanta

Integrative Logic Earns 2010 AMY Award for Work with Galderma Labs

ATLANTA, Ga. /Advertising Industry Newswire/ — Integrative Logic, a leading full-service, integrated database marketing provider, earned a 2010 Atlanta Marketer of the Year (AMY) Award from the Atlanta Chapter of the American Marketing Association for Differin.com. The 2010 AMY Awards are open to corporate and agency marketing professionals in Georgia.

Entries are scored according to the following criteria:
* How well did the program deliver measurable business results?
* Did the program successfully execute marketing best practices?
* Was the program based on sound business and marketing strategy?

The primary target for the Website is U.S. teens with acne. A secondary target is parents (mostly moms) of U.S. teens with acne (i.e.: adult “influencers”). A tertiary target audience is other U.S. adults with acne.

The content-rich site features many acne education opportunities. Also featured prominently on every page are four buttons: “Free Trial” (rebate), “The Scoop,” “Test Your Acne IQ” and “Get Personal” (registration for eCRM program) – all geared to educate visitors on acne as a medical condition and the importance of physician treatment. Visitors may also register for Galderma’s “Take Charge” newsletter (eCRM) program, which provides valuable acne treatment tips as well as product offers from Differin.

About Integrative Logic:
Integrative Logic is a direct-to-consumer marketing company serving clients in the United States, Canada, Europe, Mexico and the Caribbean. Ranked by Inc. magazine as one of the top 1200 fastest growing private companies in America, Integrative Logic is a leader in delivering highly effective, trackable, digital marketing solutions for companies across a range of verticals. Clients include Galderma Laboratories, Marriott(R) and Renaissance(R) Caribbean & Mexico Resorts, Alabama Policy Institute, Kohl’s, Stein Mart, Charming Shoppes and BioLab.

For more information visit www.integrativelogic.com .

Eularis

Pharmaco Marketing: Eularis Reports Help Do More for Real Growth

LONDON, U.K. /Advertising Industry Newswire/ — The pharmaceutical industry is facing unprecedented challenges on many fronts – a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results. Therefore, given these challenges, today is the worst time in the history of pharmaceuticals to be a pharmaceutical marketer.

Eularis has updated its reports that focus on specific key issues for pharma marketers that help them understand how to handle these specific situations. These reports uncover practices to predict how and where pharmaceutical marketing and sales investments will yield the highest market share and market share price and highlight real life case studies.

Readers will benefit from the step-by-step guidelines on successfully implementing approaches for real and measurable results available only in these reports.

Details about these updated reports can be found at:

www.ePharmaROI.com : How to Harness the Power of Social Media in Pharmaceutical eMarketing.

www.pharmaprelaunchroi.com : Pre-Launch Planning: Priming your Pharmaceutical Brand for Profit and Success.

www.GenericsDefenseStrategies.com : How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation.

www.PatientAdherenceROI.com : Ensuring Profitable Patient Adherence Programs: Using Analytics and Metrics to Improve the Bottom Line

www.PharmaIndustrySFE.com : Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?

www.PharmaMarketingROI.com : Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line.

About Eularis:
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance.

The company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit www.eularis.com .

Celox Gauze

CityMade Logistics to market Celox™ – Battlefield and hospital tested medical product used to clot blood, stop bleeding

BUFFALO, N.Y. /Advertising Industry Newswire/ — U.K. Medical products manufacturer MedTrade Products Ltd. has selected CityMade Logistics to manage the sales, marketing and distribution of Celox(TM) blood clotting products throughout the U.S. and Canada. The 10-year-old Buffalo-based company will provide these services through CityMade Logistics – CityMade’s eCommerce, Fulfillment and Logistics division.

Celox GauzeCelox over-the-counter blood clotting products stop all types of bleeding – from mild to moderate to even potentially life threatening arterial bleeding – fast. Battlefield and hospital tested, Celox works independently of the body’s normal clotting process and its clotting ability has been proven to work even in the presence of common anti-coagulant blood thinning medications like Coumadin(R), Warfarin and Heparin. Celox is also safe for children.

“There are an estimated 40 million people in the U.S. alone who take anti-coagulant blood thinning medications and are at risk if they suffer even a small cut or scrape,” said Celox North America CEO, Madonna Spitler. “We believe Celox will potentially have a significant, positive impact on them and anyone who suffers a mild to severe bleeding wound or injury.”

“When Celox comes into contact with blood, it quickly swells, gels and binds to form a gel-like clot that stops bleeding fast,” Spitler explained. “And Celox products are easy to use – just open the package, pour or pack, and apply pressure. It’s that simple. Celox is a truly remarkable product.”

Celox is available in three formulas: Celox granular can be poured directly on a wound or injury and when pressure is applied, bleeding stops typically within 30 seconds. Celox Gauze products – Gauze Roll and Gauze Pads – are imbedded with full-strength Celox granules and can be placed atop or directly inside a bleeding wound or injury. Celox Nosebleed formula is a small, specially shaped Celox-imbedded pad that can be easily inserted into the nostril to stop nosebleeds. The products retail for between $13 to under $30.

“Because Celox products are lightweight and compact, they’re easy to carry in your car, purse, briefcase, gym bag, backpack, tool box, tackle box, first aid kit – just about anywhere,” Spitler said. “Celox is great to have on hand in the kitchen, if you work with mechanics’ or carpentry tools, if your family plays sports, or if you go hunting, hiking, fishing, boating or camping. Sometimes when you’re injured, you could be miles from help. Whether you’re at home, in the middle of the woods or the middle of the lake, when you’re waiting for help for yourself, a friend or a child, minutes can seem like hours. Celox can help.”

For more information or to place an order, visit www.celoxsales.com or call 1.866.99CELOX.

CityMade Logistics’ parent company, CityMade, Inc. filed the Celox dba and also recently announced a Direct Public Offering (DPO) of 800,000 shares of common stock to investors. The DPO is registered with the federal Securities and Exchange Commission and the State Attorney General’s Office. More information is available at www.citymade.com/dpo .

Eularis

New report from Eularis: Pharmaceutical eMarketing using Social Media – How to Use It Effectively

NEW YORK, N.Y. and LONDON, U.K. /Advertising Industry Newswire/ — Eularis is announcing the release of its report “How To Harness The Power Of Social Media In Pharmaceutical eMarketing.” This report puts to rest the issues around “can’t,” and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives. “I see this common belief that social media is too difficult to implement effectively in Pharma, given the regulatory and legal hurdles, and of course the lack of ability to measure financial impact of the activities,” said the author of the report, Dr. Andree K. Bates, President of Eularis.

Eularis emarketing report“Certainly there are challenges, and adverse event (AE) reporting is a key concern of many companies due to the lack of control over it in this kind of media. However these concerns are overstated. The reality is that a recent study by BuzzMetrics found that only 1 in 500 messages on health related message boards and social networks was eligible to meet all four of the FDA’s AE reporting criteria. Given most online communities discourage the use of personally identifiable information this is what one would expect. By carefully utilizing social media as part of an integrated, carefully planned campaign – especially given that these emerging social media tools are inexpensive to implement and have already been proven to be highly effective for gaining prescriptions – we should not be as fearful in our industry as we appear to be.”

This comprehensive report addresses the most common legal and regulatory concerns of pharma and shows how a social media campaign that is built on strategy and a deep knowledge of the audience can be powerful and should not be feared. It also examines in great detail specific tools in the social media age, observing how patients, physicians and pharma companies currently use blogs, social networking, Twitter, YouTube, Google, Wikis and other social media tools… and develops best practices for their use in Pharmaceutical eMarketing. Finally, the report ties it all together, examining key case studies of healthcare social media eMarketing campaigns, giving instructions on first steps for your own campaign, and taking a closer look at measurement and achieving financial objectives.

Utilizing social media in Pharmaceutical eMarketing can be a challenge. However, with some company initiative, firm goals and the insider knowledge provided by this report, marketers can also find social media to be an empowering opportunity for their brands.

To purchase this report, please visit: www.epharmaroi.com.

About Eularis

Eularis provides sophisticated Pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps Pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance, knowing where to focus and how to budget, for maximum financial return. Co-headquartered in London and New York City, the company has developed significant experience in the global Pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer, and many others. For more information about Eularis, visit www.eularis.com.

Eularis

Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London

LONDON, U.K. — Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you are making the wrong marketing decision. The Pharmaceutical Industry is under significant pressure to consider its costs very carefully. Since marketing budgets often represent a major portion of a company’s cost base, they can easily become the target of budget cuts. The pressure to measure marketing return and effectiveness has never been stronger.

Eularis pharma seminarCurrently, much budget is spent despite marketers being unable to identify which combination of activities has the greatest growth potential, and without knowing what specific effect individual activities are having on market share. This MasterClass will show attendees the main approaches now available that can help a company determine where and how its marketing activities can work together and which synergistic combinations will deliver profitable value growth. Dr. Andree Bates will also provide attendees with ideas on how to put return measurements to work for their own brands.

Dr. Bates has already guided hundreds of Pharmaceutical Marketing Directors to financial success with their brands. Now, she is presenting her MasterClass for one day ONLY in London, UK, on Friday, 12th June 2009. By attending the Pharmaceutical Marketing ROI MasterClass, you will be able to apply these approaches to your own marketing after the Workshop.

WHO: Eularis

WHAT: MasterClass on the latest techniques, strategies and analysis approaches for knowing how to measure financial impact of sales and marketing activities

WHEN: 12 June 2009

WHERE: 1 Northumberland Avenue, Trafalgar Square. London

About Eularis
Eularis provides sophisticated Pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps Pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance. Co-headquartered in London and New York City, although working internationally, the company has developed significant experience in the global Pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit www.eularis.com.

Eularis analytics

Market Research: Eularis Analyzes Pre-Launch Brand Planning with New Pharma Industry Report

NEW YORK, LONDON, TOKYO — In today’s environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits – until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful right from the start and provide years of business-sustaining profit. However, recent studies have shown that seven out of ten drugs launched in the last five years have failed to repay their R&D investment.

Effective marketing and sales can literally mean billions during a drug’s launch and during the lifetime value. A product’s shaping, positioning, sales uptake and market performance, with proper marketing focus and support, can translate to the elusive blockbuster. The power is there… But how can marketers deliver? More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launches, companies must engage in comprehensive pre-launch planning. But how can this be achieved effectively? Today, Eularis announces the availability of their new report, “Pre-Launch Planning: Priming Your Pharmaceutical Brand for Profit and Success.”

In this report, we examine the concept and components of effective pre-launch planning. We analyze the environment for Pharmaceuticals today. We describe the phases of pre-launch planning and look at key organizational strategies, marketing tactics, regulatory considerations, and even global issues. Finally, to help companies make tough decisions and engage in effective planning, we examine powerful pre-launch analytics techniques and case studies of success. Written for CEOs, Marketing Executives and Sales Executives, this report uncovers the factors that are effective for a highly successful launch – and the barriers against it – offering secrets to get the most out of your launch.

“Although the Pharmaceutical Industry has already widely-adopted pre-launch market research, analysis and analytics into many product launch strategies,” said the author of the report, Dr. Andree K. Bates, President of Eularis, “we are starting to see that the approaches taken in the past are insufficient in today’s turbulent environment, and companies need to carefully consider exactly what kind of analysis is required now to mount a hugely successful launch.”

Dr. Bates has gained wide recognition within the international Pharmaceutical Industry for her expertise in Pharmaceutical Marketing Analysis. In addition to this and other must-have reports for Pharmaceutical Industry marketers, she has authored many articles in peer-reviewed journals and several chapters in books on Pharmaceutical Analytics.

To purchase the Eularis report, “Pre-Launch Planning: Priming Your Pharmaceutical Brand for Profit and Success,” visit: http://www.pharmaprelaunchroi.com/index.asp or, for more information about Eularis, visit www.eularis.com.

ABOUT EULARIS

Eularis provides sophisticated Pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps Pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, Managed Care analytics, patient compliance solutions and Generics defense analysis strategies. With offices in London, New York and Tokyo, the company has developed significant experience in the global Pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

More information: http://www.eularis.com.

[tags]Eularis, Pharma Marketing Analysis[/tags]

Eularis

Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programs

NEW YORK, N.Y. — Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, “Implementing a pre-launch named patient programme – evidence of increased market share,” provides pharmaceutical companies with insight and mathematical justification into the cash market share and revenue impact of pre-launch NPPs on brands, while outlining the benefits and challenges that they create.

NPPs provide pharmaceutical and biotechnology companies with a way to ethically provide pre-launch medicines available in countries outside of the approved markets. Through these programmes, patients with a genuine unmet medical need are able to access the potentially live-saving medicines before those medicines are licensed and commercially available in their home country. By implementing an NPP, companies increase patient access to new treatment options and in turn create additional revenue opportunities.

EularisWhile many companies have employed NPPs in an effort to manage patient access, maximize market share and optimize profits, until now, no studies have been conducted reporting on the efficacy of these programmes. In a market environment where an effective launch can result in success or failure of a pharmaceutical, evidence-based strategy is essential to launching and maintaining a successful product. The study reports on the positive ROI and increased launch market share that can be achieved by using NPP programmes pre-launch. The study used a control group of brands that had not used NPP, and matched these with brands that had, across multiple countries and therapeutic categories. The paper also reports on additional non-financial benefits such as product visibility and physician cultivation and relationship development.

“The pharmaceutical industry has already widely-adopted named patient programmes into many product launch strategies,” said the author of the paper, Dr. Andree K. Bates, president of Eularis. “To date, there has been limited data available on the actual frequency, usage and clinical success of these programmes, and their ultimate impact on a product launch. This study is the first to be able to quantify the positive revenue impact that these programmes wield.”

The paper (published in the Journal of Medical Marketing, September 2008 issue) also explains the regulatory and practical challenges of implementing NPPs across Europe, including regulatory constraints and inconsistent guidelines between countries. The paper addresses the difficulties that pharmaceuticals companies face by not being able to actively promote an NPP of an unlicensed pharmaceutical, which makes it difficult for patients and physicians to learn of NPPs.

Dr. Andree K. Bates, president of Eularis, will be speaking about NPPs at CBI’s Premier Forum on Pre-Approval Access for the Bio/Pharmaceutical Industry conference in Baltimore, MD in October 2008. Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis and is speaking in Tokyo and Sydney in October on this topic also. In addition to this paper and other articles in peer-reviewed journals, she has also authored several must-have reports for pharmaceutical industry marketers, and several chapters in books on pharmaceutical analytics. To arrange an interview with Dr. Bates, please contact Catherine Allen at +1 617.779.1879 or via email at CAllen@Eularis.com.

To read the paper, “Implementing a pre-launch named patient programme – evidence of increased market share,” please visit: www.palgrave-journals.com/jmm/

About Eularis

Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

[tags]Eularis pharmaceutical analytics, Dr Andree K Bates, Implementing a pre-launch named patient programme[/tags]

08-0905-resolve_72dpi

STG Media Launches Marketing Effort for Resolve Smoking Cessation Lozenge

TEMPE, Ariz. — Nearly 1 of every 5 deaths is related to smoking. Cigarettes kill more Americans a year than alcohol, car accidents, suicide, AIDS, homicide and illegal drugs combined. Lung cancer has become the leading cause of cancer death among both men and women, and 87% of lung cancer deaths are caused by smoking. Several efforts have been implemented to help decrease this problem including a recent $500 million dollar anti-smoking campaign launched by billionaires Bill Gates and Mayor Michael Bloomberg. STG Media Corp. is doing their part to help fight the growing epidemic by launching the creatively designed smoking cessation product, Resolve. Resolve is the first, scientifically tested, all-natural antidepressant and smoking cessation lozenge.

Resolve smoking cessation lozenge“We want to do our part to help to battle the problems that are associated with smoking,” CEO of STG Media Corp, Thomas Lark said. “Consumers need to know that there is an innovative and artistically designed smoking cessation product on the market that can really help people kick the habit. Our campaign will cater to the needs of a person who wants to make a healthy lifestyle change by abstaining from smoking.”

STG Media Corp has also repackaged the smoking cessation product in preparation for c-store distribution and will be launching this innovative product into 100,000 convenience stores over the next year.

“We expect Resolve to thrive in the c-store channel, we have designed product packaging and a media campaign that will specifically cater to the c-store demographic and ensure a successful launch,” Lark said.

Additionally, STG Media Corp will be launching an internet-selling-site that will make the smoking cessation product available to the online consumer. The media that Resolve will be running will drive consumers to the website to purchase the innovative product. The multi-channel marketing will offer customers more than one way to purchase Resolve, and ultimately increase the chances of acquiring a higher ROI.

Please visit Resolve’s website at http://www.tryresolve.com.

STG Media Corp., STG Retail Direct, and STG Interactive, LLC, work together to develop and execute strategic, national marketing campaigns. Based in Tempe, AZ, STG Media is a full-service advertising agency specializing in creative and media buying for print, television and radio. STG Retail Direct places products directly on the shelves of Wal-Mart, Walgreens, CVS, Target, GNC, and thousands of grocery and convenience stores nationwide. Helping clients to maximize their ad dollars, STG works hand in hand with STG Distribution Services, a master distributor and brand management company with capabilities to place products on the check-out counters in over 100,000 C-Stores in the USA with a proven market blitz program. STG Interactive develops cutting-edge E-commerce solutions in addition to search engine optimization and search engine marketing. STG helps clients navigate through the complex landscape of opportunities that exist within the context of modern, cross-media campaigns. For more information about the STG family of companies, call toll-free: 866-834-4370.

[tags]Resolve smoking cessation lozenge, STG Retail Direct, CEO Thomas Lark[/tags]

Eularis analytics

Branded Pharmaceutical Companies Can Expect to See Sales Drops of up to 70 Percent After Patent Expiration from Generic Competition

NEW YORK, N.Y. and TOKYO, JAPAN — Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of this year, Branded drug patents accounting for sales of more than $80 Billion will expire, resulting in major losses in company profits. In the United States, the Generics Industry claims more than 50 percent of all prescriptions filled. Even in Japan, where Generics penetration is notoriously low, changes are afoot. The government has taken note from countries like the U.S. and instructed all national hospitals to actively use Generics.

Now, in Japan, doctors and pharmacists can collect additional fees for prescribing and dispensing Generics. Combine these trends with a growing number of Japanese blockbuster drugs facing patent expiration and the Generics penetration rate is poised to expand in coming years, even in the ‘Generics-proof’ Japanese market. To address this globally alarming issue, Eularis announces today the availability of their new report, “How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation.”

Written for CEO’s, Marketing Executives and Sales Executives, this report uncovers the factors working for Generics growth and the barriers against it, offering secrets the Generics Industry doesn’t want you to know. The report includes case studies of how to analyze where weaknesses exist within your Generics competitors and what to do about it. The report discusses appropriate tactics to improve competitiveness with Generics and demonstrates implementation methods and issues. The report delves into specific marketing situations – such as USA, Europe and Japan – and identifies issues relevant to each market.

“Pharmaceutical companies need to seriously reconsider their approach to solving the Generics problem,” commented Dr. Andree K. Bates, author of the report and President of Eularis. “The Generics threat is very real, and growing. However, Generics are not all-powerful, invulnerable competitors. To truly mount an effective defense against Generics, companies must realize what’s hurting Generic growth and use these issues to develop a path that works to help Branded Pharma.”

Effective defense strategies exist that employ a variety of reactive and proactive measures. More importantly, the report shows that the Generics Industry is facing some powerful challenges and damaging growing pains in its path towards dominance. To truly understand the Pharma Industry’s ability to deflect the Generics threat, companies must know the best defense strategies. However, they also must know the reality of what’s happening in the Generics realm.

Bates has gained wide recognition within the international Pharmaceutical Industry for her expertise in Pharmaceutical Marketing Analysis. In addition to this and other must-have reports for Pharmaceutical Industry marketers, she has authored many articles in peer-reviewed journals and several chapters in books on Pharmaceutical Analytics.

To purchase the Eularis report, “How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation,” visit: http://www.genericsdefensestrategies.com/ or, for more information about Eularis, visit www.eularis.com

ABOUT EULARIS
Eularis provides sophisticated Pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps Pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance.

Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, Managed Care analytics, patient compliance solutions and Generics defense analysis strategies. With offices in London, New York and Tokyo, the company has developed significant experience in the global Pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

[tags]Eularis pharmaceutical analytics, pharma marketing teams, patient compliance solutions, drug market research[/tags]

Eularis Addresses Marketing Return at Japanese Pharma Marketing Excellence Conference

TOKYO and LONDON, UK — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, delivered a presentation on how to tell if you are making the wrong marketing decision at the Pharmaceutical Marketing Excellence conference in Tokyo, Japan, May 19th. Dr. Bates will delivered a presentation titled, “How to Tell if You are Making the Wrong Marketing Decision Using Marketing ROI.” Bates exposed the limitations of current measurement techniques used to guide current marketing decisions. She will also provide attendees with ideas on how to put return measurements to work in making marketing decisions for their own pharmaceutical organizations.

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. Under Bates’ leadership, Eularis issued three related research reports in the past year, including: “Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line,” “Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?,” and “Ensuring Profitable Patient Adherence Programs by Effectively Using Analytics to Release the Hidden Value Available to the Bottom Line from Adherence.”

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions.

Co-headquartered in London and New York City, although working internationally, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

More information about Eularis: http://www.eularis.com.

[tags]Dr. Andree Bates, pharmaceutical analytics company Eularis[/tags]

Dr. Andree Bates

Pharmaceutical Market Research Summit: Eularis to Address Making the Right Research Decision for ROI

NEW YORK, N.Y. and LONDON, U.K. — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return.

At 11:45 a.m. on Tuesday 29 April 2008, Dr. Bates will deliver a presentation titled, “How to Tell if You Are Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return.”

Dr. Andree BatesBates will challenge the conference attendees and will expose where both traditional market research and ROI can go wrong when used to guide marketing decisions return. She will also provide attendees with ideas on how to utilize market research data to provide input into ROI measurement for their marketing teams.

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. Under Bates’ leadership, Eularis issued three related research reports in the past year, including:

“Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line” (http://www.pharmamarketingroi.com/),

“Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things?” (http://www.pharmaindustrysfe.com/), and

“Ensuring Profitable Patient Adherence Programs by Effectively Using Analytics to Release the Hidden Value Available to the Bottom Line from Adherence” (http://www.patientadherenceroi.com/).

The 3rd Annual Pharmaceutical Market Research Summit takes place in Philadelphia. The summit program features detailed case studies from some of the industry’s most prominent organizations and provides information needed to improve market research initiatives.

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

[tags]Dr Andree Bates, Pharmaceutical Market Research Summit, Making the Right Research Decision for ROI, Eularis pharma analytics[/tags]

Eularis Exposes Hidden Barriers to Patient Adherence with New Pharmaceutical Industry Report

Non-Adherence Shown to Significantly Impact Patient Health and Financial Performance of Pharmaceutical Companies

NEW YORK, N.Y. and LONDON, U.K. — Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, “Ensuring Profitable Patient Adherence Programs.” This report analyzes the underlying barriers to patient compliance and studies how pharmaceutical companies can implement successful adherence programs that will improve patient care while also increasing profitability.

Written for CEOs, marketing executives and sales executives, this report uncovers that while adherence programs are designed to target the obvious reasons for non-compliance, including lack of insurance coverage, poor doctor-patient communication, preference for alternative therapies or simply forgetting, they are often ineffective. The report suggests that this is because there are barriers in the pharmaceutical companies themselves that may be hindering compliance program success. These barriers include such things as siloed organizational structures, privacy issues, short lifecycle of brand managers and difficulty of measuring return on investment.

“Pharmaceutical companies need to reconsider their approach to solving the patient adherence problem and stop viewing non-compliance as ‘the patient’s problem,'” commented Dr. Andree K. Bates, author of the report and president of Eularis. “In order to implement successful adherence programs that will improve patient care and increase profitability, companies should take an analytical approach that examines all non-compliance data relating to each brand, including how that brand is managed and what the financial impact of non-compliance on that brand is before designing appropriate interventions.”

An estimated 70 percent of patients who begin a pharmaceutical therapy discontinue it within one year, even those with chronic conditions that require ongoing treatment or those taking chemotherapy to prevent cancer recurrence. Given recent press reports of drug safety issues, as well as declining sales, greater competition, weaker pipelines, and increasing pressure to reduce direct-to-consumer (DTC) advertising, pharmaceutical companies can no longer ignore the hidden value available by increasing patient adherence.

The report identifies and provides insight into key elements that affect patient compliance, such as:

* Underlying patient reasons for non-adherence
* How pharmaceutical companies can measure the financial impact of non-compliance
* Program approaches for improving patient adherence
* Tips for better patient-physician communication
* Steps to increase patient adherence

The report also presents case studies that demonstrate how to effectively implement various adherence program approaches for several drug categories.

In closing, Bates said, “Adherence to prescribed medications, particularly for long-term therapies, poses a tremendous challenge to the world’s pharmaceutical companies. Investigating brand-specific compliance rates, understanding the larger causative factors for lack of compliance, and developing and implementing programs to increase compliance can help brand managers increase market share and revenues for their brands while significantly improving clinical outcomes for patients.”

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. In addition to this and other must-have reports for pharmaceutical industry marketers, she has authored many articles in peer-reviewed journals and several chapters in books on pharmaceutical analytics.

To purchase the Eularis report, “Ensuring Profitable Patient Adherence Programs” visit: www.patientadherenceroi.com or for more information about Eularis visit www.eularis.com

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

More information about Eularis: http://www.eularis.com.

All trademarks acknowledged.

[tags]Ensuring Profitable Patient Adherence Programs, Eularis pharmaceutical analytics, nternational pharma industry[/tags]

Eularis analytics

Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London

NEW YORK, N.Y. and LONDON, U.K. — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry. On Wednesday 26 March 2008, Dr. Bates will deliver a presentation titled, “Are You Up to the Challenge of Measuring ROI in Changing Dynamics of the Pharma Industry?”

Bates will challenge the thinking of conference attendees and will expose where ROI goes wrong when used to guide current marketing decisions in a changing dynamic market such as pharma. She will also uncover what opportunities are available in this environment, and what can and should be measured for real results when the environment is dynamic.

EularisBates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. Under Bates’ leadership, Eularis issued three related research reports in the past year, including: Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line (http://www.pharmamarketingroi.com), Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things? (http://www.pharmaindustrysfe.com), and Ensuring Profitable Patient Adherence Programs by Effectively Using Analytics to Release the Hidden Value Available to the Bottom Line from Adherence (http://www.patientadherenceroi.com).

The conference will be focused on answering three pivotal areas: “Addressing the Challenges in Measuring ROI” and “Ensuring the Sales and Marketing Functions are Aligned” and “Leveraging Your Brand Potential.”

To arrange an interview with Eularis www.eularis.com, please contact Tracey Haefele at +1-646-673-8408 or via email THaefele@Eularis.com.

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance.

Eularis offers pre-launch analytics, marketing mix modeling, portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Eularis has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

All trademarks acknowledged.

[tags]Eularis pharmaceutical analytics, Measuring Marketing ROI in Pharma Conference, Dr Andree Bates[/tags]

quarterback Tom Brady

Myo-Med, Tom Brady and STG Media Corp. Team Up to Tackle 2008 Advertising Campaign

TEMPE, Ariz. — Superbowl quarterback, Tom Brady has agreed to be the face of Myo-Med, for the launch of their 2008 media campaign. BioForce, the makers of Myo-Med, recently appointed STG Media Corp. as their agency of record to assist them in creating brand awareness among athletes and arthritis sufferers nationwide.

“We chose to work with STG Media Corp. to develop our print advertising strategy based on the company’s wide range of knowledge in the advertising arena,” President of BioForce, Wayne Beckstead said. “We wanted an advertising agency that doesn’t just place ads, but develops strategic print media plans that support our retail launch and direct response program. We chose to work with STG because of their proven track record in the industry. We want to develop a clear strategy that will bring our products to the forefront of the joint, pain, and athletics market.”

quarterback Tom Brady Some of the athletes to find relief by using Myo-Med include NFL athletes, such as, LaDainian Tomlinson, Willie McGinest, and two-time Super Bowl MVP, Tom Brady, as well as three-time WNBA MVP and Olympic Gold Medalist basketball player Lisa Leslie. Along with helping athletes, BioForce has also focused on creating a product that caters to the needs of people with chronic muscle pain and arthritis. BioForce has consulted a large group of health care professionals specializing in muscle pain, arthritis and joint relief for the development of their product. Myo-Med and STG will work together to educate consumers of the all of the benefits the pain relief product can provide.

“We plan on differentiating Myo-Med from other topical pain relief brands on the market, by developing a media strategy that targets the arthritic, sports and chronic muscle suffers separately and strategically,” CEO of STG Media Corp., Thomas Lark said. “We look forward to working in collaboration with Myo-Med to create one of the top pain relief products on the market.”

About STG
STG Media Corp., STG Retail Direct, and STG Interactive, LLC, work together to develop and execute strategic, national marketing campaigns. Based in Tempe, AZ, STG Media is a full-service advertising agency specializing in creative and media buying for print, television and radio. STG Retail Direct places products directly on the shelves of Wal-mart, Walgreens, CVS, Target, GNC, and thousands of grocery and convenience stores nationwide. STG Interactive develops cutting-edge E-commerce solutions in addition to search engine optimization and search engine marketing. As the line between brand marketing and direct response blurs, brand advertisers move to be more accountable, and direct response marketers evaluate themselves from a brand perspective. STG helps clients navigate through the complex landscape of opportunities that exist within the context of modern, cross-media campaigns.

For more information about the STG family of companies, call toll-free: 866-834-4370 or visit: http://www.stgpress.com.

About Myo-Med
Myo-Med is the flagship product of BioForce, a health products company dedicated to naturally improving the quality of life for people of all ages. Myo-Med was created by health professionals and is recommended by doctors and athletes for those who refuse to let sore muscles, arthritis, or backache get in the way of living. Myo-Med provides pain relief through all-natural, toxin-free ingredients. Myo-Med’s proprietary, all-natural nano delivery system carries anti-inflammatory ingredients deep into affected tissue to provide fast, lasting relief. It has been used effectively by those suffering such pain-causing ailments as arthritis, sports injuries, backache, strains, bruises and sprains.

All trademarks acknowledged.

[tags]quarterback Tom Brady, STG Media Corp, BioForce Myo-Med, media buying for print, STG Retail Direct, sports endorsements, CEO Thomas Lark[/tags]

Healthcare Communications

Saatchi & Saatchi Healthcare Communications Group Teams with Google and Yahoo! in Tech Circuit Training

Staffers from all SSHCG agencies will partner with a highly sophisticated group of personal tech trainers from Google and Yahoo! to learn the newest ways to incorporate digital technology into client marketing.

NEW YORK, N.Y. — Brand teams at a leading New York healthcare communications group are taking their digital skills to the next level at a day-long Tech Fit fair on Tuesday, February 12, 2008, at Saatchi & Saatchi Healthcare Communications Group (SSHCG) headquarters in lower Manhattan. According to Sam Welch, SSHCG president, “Tech Fit isn’t the usual show and tell one-off. It is the latest innovation in SSHCG’s ongoing program of digital training, which has been a strong focus for the group for several years. This new kind of circuit training, part of our mission to inspire healthier living, will be a great workout with a serious purpose – cutting-edge results for our clients. Tech Fit is that rare instance of all gain, no pain.”

Healthcare Communications Staffers from all SSHCG agencies will partner with a highly sophisticated group of personal tech trainers from Google and Yahoo! to learn the newest ways to incorporate digital technology into client marketing. After the day’s interactive circuit training ends, brand teams are charged with developing plans for enhancing strategic client programs with the latest new media tools.

Stations along the training circuit feature such digital and healthcare luminaries as Sermo, Revolution Health, iMed, Ugen Media, Vibrant Media, MedTrackAlert, Pulse Media, About.com, Moey, Pointroll, Pulse Media, Tobii and Toonboom. SSHCG brand teams will gain hands-on experience with the latest new media options as they traverse the circuit.

“The goal of Tech Fit is to keep improving our digital skills and ensure that employees share in that knowledge,” said Welch, “This fits with SSHCG’s holistic approach to marketing, integrating new and traditional channels to keep giving clients the best options.” Tech Fit involves all SSHCG agencies, including Saatchi & Saatchi Healthcare Innovations, Saatchi & Saatchi Healthcare Advertising and Saatchi & Saatchi Consumer Health+Wellness.

About Saatchi & Saatchi Healthcare Communications Group
Saatchi & Saatchi Healthcare Communications Group (SSHCG), a member of Publicis Healthcare Communications Group, consists of three distinct agencies providing integrated and holistic marketing solutions to its clients: Saatchi & Saatchi Consumer Health+Wellness, dedicated to motivating healthy consumer behavior; Saatchi & Saatchi Healthcare Innovations, providing innovative solutions in the challenging healthcare environment; and Saatchi & Saatchi Healthcare Advertising, keeping clients out in front of the healthcare industry. All three agencies strive to be strategic brand stewards for their clients, applying best-in-class planning, creative and account service across all marketing disciplines including advertising, promotion, digital, CRM and professional marketing. All the teams attack marketing in the same manner: insights come first to drive solid strategy followed by executional excellence. Web site: www.saatchihealthcare.com .

About Publicis Healthcare Communications Group
Publicis Healthcare Communications Group (PHCG), a member of Publicis Groupe SA, is one of the largest healthcare communications groups in the world with over 2,700 employees located in 10 countries. Worldwide healthcare services include advertising, medical education, sales and marketing, and medical and scientific affairs. PHCG offers its clients a strategic partnership, a strong focus on ensuring value for their marketing spend, and exceptional performance on their assignments. Web site: www.publicishealthcare.com .

About Publicis Groupe
Publicis Groupe (Euronext Paris: FR0000130577) is the world’s fourth largest communications group. In addition, it is ranked as the world’s second largest media counsel and buying group, and is a global leader in digital and healthcare communications. With activities spanning 104 countries on five continents, the Groupe employs approximately 44,000 professionals.

The Groupe offers local and international clients a complete range of communication services, from advertising, through three autonomous global advertising networks, Leo Burnett, Publicis, Saatchi & Saatchi and two multi-hub networks, Fallon and 49%-owned Bartle Bogle Hegarty; to media consultancy and buying, through two worldwide networks, Starcom MediaVest Group and ZenithOptimedia; interactive and digital marketing led by Digitas; Specialized Agencies and Marketing Services (SAMS) offering healthcare communications, corporate and financial communications, public relations, CRM and direct marketing, event communications, sports marketing and multicultural communications. Web site: www.publicisgroupe.com .

All trademarks acknowledged.

[tags]SSHCG president Sam Welch, Saatchi & Saatchi Healthcare Communications Group, Publicis Healthcare Communications Group, Tech Fit fair[/tags]

Eularis analytics

Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference in London

NEW YORK, N.Y. and LONDON, U.K. — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on marketing return at the Pharmaceutical Marketing Society Half-day Conference: ROI or RIP. At 2:30 p.m. on Monday 26 November 2007, Dr. Bates will deliver a presentation titled, “What Can Be Measured?”

Bates will challenge the thinking of conference attendees and will expose where ROI goes wrong, the limitations of ROI and what can and should be measured. She will also provide attendees with ideas on how to put ROI to work in their own pharmaceutical organizations.

Eularis analyticsBates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. Under Bates’ leadership, Eularis issued two related research reports this year, including Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things? (http://www.pharmaindustrysfe.com/) and Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line (http://www.pharmamarketingroi.com/).

The Pharmaceutical Marketing Society Half-day Conference takes place in London. The conference will be focused on answering two pivotal questions: “Are you maximizing the return on investment from your marketing spend?” and “Do you know where your marketing spend is having the most effect?” For more information, visit: http://www.pmsociety.org.uk/events/roi.

To arrange an interview with Eularis, please contact Jennifer Humiston at +1 617.779.1812.

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions.

Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

All trademarks acknowledged.

For more information about Eularis, visit http://www.eularis.com.

[tags]Dr Andree Bates, pharma analytics company, Eularis, Pharmaceutical Marketing Society[/tags]

Marketing Research: Maximizing the Bottom Line in Pharmaceutical Marketing

LONDON, U.K. — Eularis is announcing the release of an update to its report, “Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line.” Originally offered in February 2007, the comprehensive report has been revised to provide pharmaceutical marketers with a competitive edge and the latest research information.

“The pharmaceutical environment is turbulent, and what used to work to create an industry-wide growth of 20 percent, no longer does,” said the author of the report, Dr. Andree K. Bates, president of Eularis. “As market growth slows, the bottom line return for brands is under increased scrutiny, and every marketing dollar must count.”

Eularis identified a common problem faced by pharmaceutical companies – how to know which activities impact market share and by how much. The company assembled a group of world-leading mathematicians in the predictive analytics field, as well as thought leaders, to find the solution.

This report, in turn, analyzes how top pharmaceutical marketing leaders are handling pressing marketing return issues, and offers new ideas to apply. The detailed research addresses issues such as: ROI basics; practical skills marketers need for measuring marketing effectiveness; tools and best practices that make a difference; measurement principles that drive successful marketing measurement; how to propel strategy, growth, and bottom line return; plus an array of case studies.

The report also explains what real people did to measure, improve, and prove bottom line return. It uncovers practices to predict how and where pharmaceutical marketing and sales investments will yield the highest market share and market share price. Readers will benefit from the step-by-step guidelines on successfully implementing approaches for real and measurable results available only in this report.

Dr. Andree Bates, president of Eularis, has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis and is the author of this must-have report for all pharmaceutical industry marketers.

To purchase this report, visit: http://www.pharmamarketingroi.com

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance.

Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

All trademarks acknowledged.

[tags]pharma marketers and market research, Eularis pharmaceutical analytics[/tags]

Eularis analytics

Eularis is Reshaping Pharmaceutical Analytics Under New Corporate Identity

NEW YORK, N.Y. and LONDON, U.K. — Campbell Belman, an established pharmaceutical analytics company, today introduces its new name: Eularis. This announcement reflects the significant growth the Company has achieved across its full range of pharmaceutical analytics products, which have helped tailor the advertising and marketing programs of its global top-tier clients, including AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck, Novo Nordisk and Pfizer.

Eularis’ flagship product, the 94.8 Analytics Process, offers a more mathematically accurate approach to determining the ROI of pharmaceutical marketing by combining up-to-the-minute market data with advanced predictive algorithms. This avoids the inherent flaws of traditional analytics approaches, which rely heavily on historical or analogue data. The 94.8 Analytics Process better accounts for recent changes in the marketplace, allowing companies to better direct marketing and advertising spending to increase revenues and market share.

Eularis analytics “The pharmaceutical industry is unique in the level of structural and environmental change it has experienced over the past 20 years. In the current market, where challenges such as product recalls, decline in access to physicians, new restrictions on promotional policy and emergence of legally aggressive generics have come into play, methods that rely on historical data yield reduced accuracy when it comes to predicting future prescribing,” commented Dr. Andree K. Bates, president, Eularis. “By collecting current up-to-date market data as part of each individual client’s analytics program, Eularis can utilize a snapshot of the current market to avoid the limitations of conventional predictive models and achieve improved accuracy in predicting reactions to promotional activities.”

In addition to the 94.8 Analytics Process, Eularis also offers in-depth analytics approaches for individual marketing programs, such as patient compliance analytics and sales force analytics, as well as pricing analytics, corporate branding analytics, and R&D analytics.

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance.

Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit www.eularis.com .

[tags]Eularis pharmaceutical analytics, ROI of pharma marketing, Campbell Belman, 948 Analytics Process, Dr Andree K Bates[/tags]